IPO Calendar: Upcoming US IPOs

A running list of upcoming and recently priced US IPOs, updated weekly. Dates, price ranges and deal sizes change frequently ahead of pricing — treat the table below as a snapshot as of August 3, 2026, and confirm details before making any decision.

Upcoming and Recent IPOs

Company	Ticker	Price Range	Est. Deal Size	Expected Date
Apnimed	APMD	$16.00	$192.0M	Priced 7/31/2026
Churchill Capital XIII (SPAC)	XIIIU	$10.00	$360.0M	Priced 7/31/2026
East West Ave Acquisition Corp. (SPAC)	EWAVU	$10.00	$100.0M	Priced 7/31/2026
ARC Group Securities Acquisition I (SPAC)	FJDIU	$10.00	$105.0M	8/4/2026
BOA Acquisition Corp. II (SPAC)	THEOU	$10.00	$125.0M	8/4/2026
Attovia Therapeutics	ATTO	$15.00–$17.00	$200.0M	8/5/2026
Braveheart Bio	BRVE	$15.00–$17.00	$300.0M	8/6/2026
Vogenx	VOGX	$11.00–$13.00	$75.0M	8/6/2026
Web3Labs Global	MDAT	$4.00–$5.00	$28.1M	Week of 8/7/2026
BW Industrial Holdings	BWGC	$6.00–$7.00	$17.1M	Week of 8/10/2026
MetaOptics (uplisting)	MOT	$5.00–$7.00	$18.0M	Week of 8/10/2026
Riku Dining Group	RIKU	$4.00–$6.00	$25.0M	Week of 8/10/2026

What to Watch

• A biotech IPO wave lands this week. Attovia Therapeutics prices Wednesday (8/5), and Braveheart Bio and Vogenx both price Thursday (8/6), together targeting over $500 million raised. Braveheart is developing an oral cardiac myosin inhibitor for hypertrophic cardiomyopathy; Attovia is testing a therapy for chronic itch conditions targeting the IL-31 pathway. Three biotechs pricing in the same window is typically a sign that bankers see a receptive window for the sector — it can close quickly if early deals price or trade poorly.
• Four SPACs in the mix. Churchill Capital XIII and East West Ave Acquisition Corp. already priced Friday; ARC Group Securities Acquisition I and BOA Acquisition Corp. II are set to price Tuesday (8/4). These are blank-check companies — they raise money first and identify an acquisition target later, a fundamentally different risk profile from a standard operating-company IPO.
• Private markets are opening up too. Fintech broker Clear Street launched a platform this week giving accredited investors indirect pre-IPO exposure to Databricks (last valued near $188 billion), with plans to add up to 30 late-stage private companies by year-end — a reminder that pre-IPO access is expanding well beyond the public IPO calendar.

Fact vs. estimate: tickers, price ranges and deal sizes reflect terms as filed/marketed at time of writing and can change before pricing. Expected dates for deals not yet priced are estimates.

Why It Matters for Pre-IPO and Tokenized Equity Investors

Most names on a public IPO calendar are companies that were pre-IPO investments not long ago. Watching which sectors are actively pricing (biotech this week, SPACs persistently active through 2026) is a useful read on where public-market appetite currently sits — and by extension, which categories of still-private companies may find a receptive IPO window if they choose to list next.

This material is for informational purposes only and does not constitute individual investment advice.

Sources

• IPOScoop — IPO Calendar
• BioPharma Dive — Braveheart, Attovia join next wave of biotech IPOs
• Fierce Biotech — Attovia, Braveheart and Vogenx seek more than $500M across trio of IPOs
• CNBC — Clear Street launches pre-IPO platform, lists Databricks